CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 443 filers reported holding CRISPR THERAPEUTICS AG in Q4 2021. The put-call ratio across all filers is 1.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $26 | +44.4% | 582 | +80.7% | 0.00% | – |
Q2 2023 | $18 | +80.0% | 322 | +50.5% | 0.00% | – |
Q1 2023 | $10 | -23.1% | 214 | -32.3% | 0.00% | – |
Q4 2022 | $13 | -100.0% | 316 | -22.0% | 0.00% | – |
Q3 2022 | $26,000 | -31.6% | 405 | -35.8% | 0.00% | – |
Q2 2022 | $38,000 | -97.8% | 631 | -97.7% | 0.00% | -100.0% |
Q1 2022 | $1,731,000 | -28.1% | 27,580 | -13.2% | 0.01% | -29.4% |
Q4 2021 | $2,407,000 | +29987.5% | 31,764 | +63428.0% | 0.02% | – |
Q2 2021 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
Q1 2021 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
Q4 2020 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
Q3 2020 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
Q2 2020 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
Q1 2020 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
Q4 2019 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
Q3 2019 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
Q2 2019 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
Q1 2019 | $8,000 | – | 50 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |